Article Text

PDF

Review: aspirin reduces the incidence of coronary artery disease in people at risk
  1. Eric R Bates, MD
  1. University of Michigan Ann Arbor, Michigan, USA

    Statistics from Altmetric.com

    
 
 QUESTION: In people at risk, what is the effectiveness of aspirin for primary prevention of coronary artery disease (CAD)?

    Data sources

    Randomised controlled trials from 1985 onward were identified by searching Medline with the terms cardiovascular disease and aspirin. Meta-analyses and review articles were also scrutinised.

    Study selection

    Studies were selected if they assessed the effectiveness of aspirin for primary prevention of CAD and assessed outcomes that included incidence of myocardial infarction (MI), stroke, all cardiovascular events (MI, stroke, and cardiovascular deaths), bleeding complications, and all-cause mortality.

    Data extraction

    Data were extracted on study sample size, patient characteristics, key components of the intervention, duration of intervention, and outcomes.

    Main results

    4 trials (48 540 patients) were included in the meta-analysis. 25 133 patients received aspirin, and 23 407 received placebo. The incidence of MI and all cardiovascular events was higher in the placebo group than in the aspirin group (table). The groups did not differ for the incidence of stroke or all-cause mortality (table). The incidence of bleeding complications was higher in the aspirin group than in the placebo group (table). For patients with risk of CAD ≥ 1.5% per year, treatment with aspirin for primary prevention was reported to be valuable and safe with benefits likely to outweigh harms (figure).

    Aspirin v placebo for primary prevention of coronary artery disease*

    Figure 1

    Absolute benefit (reduction in all cardiovascular events) (line A) and absolute harm (increase in major bleeds) (line B) from aspirin treatment, related to absolute cardiovascular event risk. The dotted lines show the 78% confidence regions. By extrapolation, benefit and harm from aspirin are equal when cardiovascular event risk is 0.22%/year, with an upper 95% confidence limit for this estimate at a cardiovascular event risk of approximately 0.8%/year.

    Conclusions

    In people at risk, aspirin reduces the incidence of coronary artery disease. This reduction is associated with an increase in the incidence of bleeding complications.

    
 
 QUESTION: In people at risk, what is the effectiveness of aspirin for primary prevention of coronary artery disease (CAD)?

    Commentary

    It is more difficult to assess treatment benefits with primary prevention than with secondary prevention because event rates are lower. This difficulty is shown again in the review by Sanmuganathan et al of aspirin treatment for primary prevention of CAD events. The absolute benefit was a 0.15% reduction per year in MI compared with an increased risk of 0.04% per year for major non-cerebral haemorrhage (non-cerebral bleeds causing death, transfusion, or operation) and 0.18% per year for non-minor haemorrhage (non-cerebral bleeds not classified as minor). Differences in stroke or all-cause mortality were not statistically significant.

    The 4 trials summarised in this paper have previously been reviewed in the sixth American College of Chest Physicians consensus conference on antithrombotic treatment.1 These authors recommended the use of 75 or 81 mg of aspirin daily for primary prevention because of lower stroke rates in the 2 trials that used this dose compared with the 325 mg daily or every-other-day doses used in the other 2 trials. They also emphasised lowering the diastolic blood pressure below 85 mm Hg in patients receiving aspirin for primary prevention. Because the bleeding risk remains constant, whereas the therapeutic benefit and the risk for cardiovascular events increase, treating higher-risk patients makes more clinical sense than does treating everyone. For risk assessment, the consensus conference authors emphasise older age and cardiac risk factors, whereas Sanmuganathan et al offer a modified Sheffield table.

    References

    View Abstract

    Footnotes

    • Theraputics

    • Source of funding: not stated.

    • For correspondence: Professor L E Ramsay, Clinical Pharmacology and Therapeutics, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK. Fax +44 (0) 114 272 1275.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.